Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

News Daily News

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Michael O'Riordan

September 16, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Industry News

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

August 31, 2015

News Industry News

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

June 22, 2015

News Daily News

Acute Hyperglycemia Worsens Post-AMI Prognosis

October 24, 2014

News Daily News

Pre-PCI Trimetazidine Strategy Reduces CIN, Myocardial Injury in Diabetic Patients with Mild-to-Moderate CKD

May 30, 2014

News Daily News

Los Subgrupos de Alto Riesgo obtienen Protección Renal de la Rosuvastatina

Caitlin E. Cox

October 11, 2013

News Daily News

High-Risk Subgroups Derive Kidney Protection from Rosuvastatin

Caitlin E. Cox

October 11, 2013

Presentation

Short-term Rosuvastatin for Prevention of Contrast-Induced Acute Kidney Injury (CI-AKI) in Patients with Diabetes and Chronic Kidney Disease

Presenter: Yaling Han

October 09, 2013

Advertisement

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

Acute Hyperglycemia Worsens Post-AMI Prognosis

Pre-PCI Trimetazidine Strategy Reduces CIN, Myocardial Injury in Diabetic Patients with Mild-to-Moderate CKD

Los Subgrupos de Alto Riesgo obtienen Protección Renal de la Rosuvastatina

High-Risk Subgroups Derive Kidney Protection from Rosuvastatin

Short-term Rosuvastatin for Prevention of Contrast-Induced Acute Kidney Injury (CI-AKI) in Patients with Diabetes and Chronic Kidney Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content